ChemoCentryx/ US16383L1061 /
19/10/2022 21:59:55 | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
52.00USD | - | 89,734 Turnover: 4.67 mill. |
-Bid Size: - | -Ask Size: - | 52.00 | 51.98 |
GlobeNewswire
27/06
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 M...
GlobeNewswire
07/05
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
05/03/2022
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Ardelyx, BioMarin, Chegg, a...
GlobeNewswire
03/03/2022
(CCXI Alert) Should Management be Held Accountable for ChemoCentryx Investors Losses? Contact Johnso...
GlobeNewswire
01/03/2022
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
GlobeNewswire
23/02/2022
ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday,...
GlobeNewswire
09/02/2022
ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
GlobeNewswire
19/01/2022
ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vascu...
GlobeNewswire
12/11/2021
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medici...
GlobeNewswire
09/11/2021
ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
GlobeNewswire
04/11/2021
Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheum...
GlobeNewswire
02/11/2021
ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 20...
GlobeNewswire
11/10/2021
ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer
GlobeNewswire
08/10/2021
ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis
GlobeNewswire
27/09/2021
ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated...
GlobeNewswire
09/08/2021
ChemoCentryx Reports Second Quarter 2021 Financial Results and Recent Highlights
GlobeNewswire
06/08/2021
Lifshitz Law Firm, P.C. Announces Investigations of 3D Systems Corp. (NYSE: DDD), Acadia Pharmaceuti...
GlobeNewswire
04/08/2021
ChemoCentryx to Participate in the Canaccord Genuity 41st Annual Growth Conference
GlobeNewswire
02/08/2021
ChemoCentryx to Hold Second Quarter 2021 Financial Results Conference Call on Monday, August 9, 2021